Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,980,304
  • Shares Outstanding, K 401,528
  • Annual Sales, $ 803,400 K
  • Annual Income, $ -747,060 K
  • 60-Month Beta 1.48
  • Price/Sales 172.75
  • Price/Cash Flow N/A
  • Price/Book 36.07
Trade MRNA with:

Options Overview

Details
  • Implied Volatility 69.62%
  • Historical Volatility 66.00%
  • IV Percentile 34%
  • IV Rank 22.20%
  • IV High 131.61% on 12/01/20
  • IV Low 51.93% on 06/08/21
  • Put/Call Vol Ratio 0.84
  • Today's Volume 83,461
  • Volume Avg (30-Day) 137,233
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 483,489
  • Open Int (30-Day) 512,756

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 6.01
  • Number of Estimates 7
  • High Estimate 8.12
  • Low Estimate 3.27
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +2,038.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
214.07 +62.81%
on 07/08/21
365.60 -4.67%
on 08/02/21
+114.23 (+48.75%)
since 07/02/21
3-Month
143.56 +142.78%
on 05/06/21
365.60 -4.67%
on 08/02/21
+162.51 (+87.36%)
since 05/03/21
52-Week
54.21 +542.93%
on 09/08/20
365.60 -4.67%
on 08/02/21
+270.55 (+346.95%)
since 08/03/20

Most Recent Stories

More News
Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

MRNA : 348.53 (+0.55%)
Is a Beat Likely for Moderna (MRNA) This Earnings Season?

Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.

AZN : 57.50 (+0.21%)
DVAX : 9.45 (+1.18%)
PFE : 44.21 (+0.57%)
MRNA : 348.53 (+0.55%)
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.

REGN : 577.13 (+0.44%)
MRNA : 348.53 (+0.55%)
PRTA : 52.74 (+5.27%)
NTLA : 136.89 (+0.23%)
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

--Moderna now has clinical programs in five different therapeutic areas

MRNA : 348.53 (+0.55%)
Pre-Market Brief: Stocks Set to Open Higher on Q2 Earnings Optimism and Improved Prospects for an Infrastructure Bill

Morning Markets Sep S&P 500 futures this morning are up +0.41% on optimism about Q2 corporate earnings results. Stocks are also garnering support from the improved prospects that the Senate will pass...

CCL : 21.50 (+0.19%)
LEVI : 28.51 (+0.04%)
INFI : 2.90 (-1.02%)
MRNA : 348.53 (+0.55%)
SQ : 271.00 (-0.51%)
Non-Farm Payrolls Due Next Week Stateside

Monday U.S. Economic Lookahead Markit manufacturing Purchasing Managers Index (final) (July) Institute ...

GPN : 173.00 (+0.70%)
RACE : 210.47 (-0.79%)
NXPI : 208.98 (unch)
BABA : 197.81 (-1.14%)
LLY : 239.00 (-3.08%)
ETN : 158.10 (+1.03%)
GWO.TO : 37.54 (+0.24%)
ZZZ.TO : 29.41 (unch)
CVS : 82.72 (+0.38%)
BKNG : 2,170.94 (-0.34%)
GM : 57.31 (+0.50%)
MRNA : 348.53 (+0.55%)
SQ : 271.00 (-0.51%)
DUK : 106.19 (+1.03%)
CCL-B.TO : 71.55 (-0.40%)
BLDP.TO : 20.20 (+0.90%)
CSU.TO : 1,998.43 (+2.24%)
D : 75.35 (+0.64%)
LBRDA : 172.93 (+0.73%)
DISH : 41.69 (-0.48%)
CLIQ.TO : 6.51 (+0.46%)
DII-B.TO : 14.17 (+0.14%)
APS.TO : 3.37 (+3.06%)
BHC.TO : 36.50 (-1.00%)
CJT.TO : 194.20 (-0.97%)
What's in Store for Amgen (AMGN) This Earnings Season?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs....

REGN : 577.13 (+0.44%)
LLY : 239.00 (-3.08%)
AMGN : 239.79 (-0.72%)
MRNA : 348.53 (+0.55%)
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

REGN : 577.13 (+0.44%)
LLY : 239.00 (-3.08%)
MRNA : 348.53 (+0.55%)
ZTS : 202.11 (unch)
Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

JNJ : 172.27 (+0.04%)
PFE : 44.21 (+0.57%)
MRNA : 348.53 (+0.55%)
PJP : 81.37 (+0.26%)
IHE : 193.04 (+0.69%)
PPH : 75.15 (+0.39%)
FXH : 122.09 (+0.03%)
IEIH : 35.81 (+0.09%)
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $345.64, marking a -1.05% move from the previous day.

MRNA : 348.53 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

3rd Resistance Point 382.81
2nd Resistance Point 374.20
1st Resistance Point 360.41
Last Price 348.53
1st Support Level 338.01
2nd Support Level 329.40
3rd Support Level 315.61

See More

52-Week High 365.60
Last Price 348.53
Fibonacci 61.8% 246.65
Fibonacci 50% 209.90
Fibonacci 38.2% 173.16
52-Week Low 54.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar